Thomas Geiger

Inhibition of interleukin-1 type I receptor expression in human cell-lines by an antisense phosphorothioate oligodeoxynucleotide.

L. Miraglia, N. Dean, T. Geiger, 1996, International journal of immunopharmacology.

Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.

D. Fabbro, N. Dean, T. Geiger, 1998, Anti-cancer drug design.

Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo.

E. Lesnik, S. Freier, D. Fabbro, 1996, Proceedings of the National Academy of Sciences of the United States of America.